Trial reportPharmacotherapy2012
Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control.
Trial report in Pharmacotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Impact of patient care teams on blood pressure control in patients with hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- A Systematic Review of Economic Evidence on Community Hypertension Interventions.American journal of preventive medicine · 2017Pooled it
- Economics of Team-based Care in Controlling Blood Pressure: A Community Guide Systematic Review.American journal of preventive medicine · 2015Pooled it
- A pharmacist intervention for monitoring and treating hypertension using bidirectional texting: PharmText BP.Contemporary clinical trials · 2020Trial
- Cost-Effectiveness of a Physician-Pharmacist Collaboration Intervention to Improve Blood Pressure Control.Hypertension (Dallas, Tex. : 1979) · 2015Trial
- A Cluster-Randomized Trial of a Centralized Clinical Pharmacy Cardiovascular Risk Service to Improve Guideline Adherence.Pharmacotherapy · 2015Trial
- A centralized cardiovascular risk service to improve guideline adherence in private primary care offices.Contemporary clinical trials · 2015Trial
- Cost-effectiveness of Wisconsin TEAM model for improving adherence and hypertension control in black patients.Journal of the American Pharmacists Association : JAPhATrial
- Instrumental variable methods to assess quality of care the marginal effects of process-of-care on blood pressure change and treatment costs.Research in social & administrative pharmacy : RSAPTrial
- The cost-effectiveness of pharmacist-physician collaborative care models vs usual care on time in target systolic blood pressure range in patients with hypertension: a payer perspective.Journal of managed care & specialty pharmacy · 2021Article
- Dissemination of a telehealth cardiovascular risk service: The CVRS live protocol.Contemporary clinical trials · 2021Article
- Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care.Current hypertension reports · 2019Review
- Economic Evaluation of the Home Blood Pressure Telemonitoring and Pharmacist Case Management to Control Hypertension (Hyperlink) Trial.Journal of the American College of Clinical Pharmacy : JACCP · 2018Article
- Team-Based Care with Pharmacists to Improve Blood Pressure: a Review of Recent Literature.Current hypertension reports · 2018Review
- Avoiding Pitfalls With Implementation of Randomized Controlled Multicenter Trials: Strategies to Achieve Milestones.Journal of the American Heart Association · 2016Review
- The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
STUDY
objectiveTo compare costs associated with a physician-pharmacist collaborative intervention with costs of usual care.
designCost analysis using health care utilization and outcome data from two prospective, cluster-randomized, controlled clinical trials.
settingEleven community-based medical offices. PATIENTS: A total of 496 patients with hypertension; 244 were in the usual care (control) group and 252 were in the intervention group. MEASUREMENTS AND MAIN
resultsTo compare the costs, we combined cost data from the two trials. Total costs included costs of provider time, laboratory tests, and antihypertensive drugs. Provider time was calculated based on an online survey of intervention pharmacists and the National Ambulatory Medical Care Survey. Cost parameters were taken from the Bureau of Labor Statistics for average wage rates, the Medicare laboratory fee schedule, and a publicly available Web site for drug prices. Total costs were adjusted for patient characteristics. Adjusted total costs were $774.90 in the intervention group and $445.75 in the control group (difference $329.16, p<0.001). In a sensitivity analysis, the difference in adjusted total costs between the two groups ranged from $224.27-515.56. The intervention cost required to have one additional patient achieve blood pressure control within 6 months was $1338.05, determined by the difference in costs divided by the difference in hypertension control rates between the groups ($329.16/24.6%). The cost over 6 months to lower systolic and diastolic blood pressure 1 mm Hg was $36.25 and $94.32, respectively.
conclusionThe physician-pharmacist collaborative intervention increased not only blood pressure control but also the cost of care. Additional research, such as a cost-benefit or a cost-minimization analysis, is needed to assess whether financial savings related to reduced morbidity and mortality achieved from better blood pressure control outweigh the cost of the intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.